Cognito Therapeutics presents new OVERTURE data at AD/PD 2026 — Spectris preserves corpus callosum and attenuates EEG slowing vs ADNI controls
Summary
Cognito Therapeutics presented new data from the OVERTURE feasibility study at the AD/PD 2026 conference in March 2026. Key findings: (1) Spectris-treated patients showed statistically significant preservation of the corpus callosum — the brain's largest white matter tract — versus sham controls; (2) brain volume was maintained (+0.58%) in Spectris-treated patients versus a decline (-0.91%) in matched Alzheimer's Disease Neuroimaging Initiative (ADNI) controls; (3) Spectris attenuated EEG slowing (the shift from higher to lower frequencies that tracks AD progression) versus sham; (4) reductions in EEG slowing correlated with reduced decline in ADCS-ADL scores and reduced MRI brain volume loss; (5) additional posters demonstrated Spectris enhancement of cognitive event-related potentials (ERPs) associated with working memory. CMO Dr. Ralph Kern said results "highlight the potential for biomarker-guided treatment and disease modification."
Why it matters
Corpus callosum preservation in an Alzheimer's device trial is a landmark structural MRI result — the corpus callosum degenerates early and rapidly in AD, and its preservation is one of the strongest possible structural evidence for disease modification. The EEG slowing attenuation correlating with both functional (ADCS-ADL) and structural (MRI volume) outcomes provides a non-invasive biomarker for tracking Spectris therapeutic response. These AD/PD data materially strengthen the case for Cognito's pivotal trial and 2027 commercial launch.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial